What's New

Foundation Funded Researchers Are Making Progress Against Genitourinary Cancers

The Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) is working to improve cancer care by funding bright young researchers and studies in all types of cancer. Foundation grantees are actively performing research studies that are improving the quality of the cancer care that you, your family, and your friends or colleagues receive. In addition, the Foundation supports meetings and educational forums for physicians and other cancer professionals where these ground-breaking studies are being presented, and where health care professionals can learn new information to improve the care of their patients.

One such meeting is the Genitourinary Cancers Symposium, being held February 14-16, in Orlando, Florida, which focuses on the latest research in genitourinary cancers.  This year, the Foundation is supporting 25 Merit Awards in Genitourinary Cancer for trainees to present high-quality research at the meeting.  In addition, many of the Foundation’s past grant and award recipients, such as the researchers listed below, are presenting important research findings at the symposium about prostate cancer, renal cell carcinoma, and urothelial cancer on a wide array of topics including new treatments and new diagnostics. To view summaries of the studies and results being presented by these Foundation-funded investigators, visit the online Meeting Program after February 12, 6:00 pm ET.

The Foundation grantees and their research titles are:

Emmanuel S. Antonarakis, MD (2009 Young Investigator Award, or YIA) – Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen-deprivation therapy in patients with biochemically recurrent prostate cancer.

Andrew J. Armstrong, MD, ScM (2006 YIA) – A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.

Rupal Satish Bhatt, MD, PhD (2006 YIA and 2012 Career Development Award, or CDA) – Inhibition of tumor growth in a VEGFR TKI-resistant model of renal cell carcinoma using dalantercept combined with sunitinib.

Toni K. Choueiri, MD (2010 CDA) – A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with pegfilgrastim support in patients muscle-invasive urothelial cancer: Safety, pathologic, radiologic, and molecular correlates.

Daniel Costin Danila, MD (2008 YIA) - Prostate-specific mRNA detection in whole blood as an analytically validated prognostic biomarker for patients with castration-resistant prostate cancer.

Darren R. Feldman, MD (2009 YIA)Phase II trial of paclitaxel, ifosfamide, and cisplatin (TIP) for previously untreated patients with intermediate- or poor-risk germ cell tumors.

Terence W. Friedlander, MD (2010 YIA) – Detection and genomic interrogation of circulating tumor cells and circulating tumor stem cells from men with metastatic castration-resistant prostate cancer.

Jorge A. Garcia, MD (2004 YIA) – A phase II study of linsitinib (OSI-906) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer.

Oscar B. Goodman, Jr., MD, PhD (2005 YIA) – Exploratory analysis of the visceral disease patient subset in COU-AA-301, a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer.

Lauren C. Harshman, MD (2009 YIA) – First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An analysis from the International mRCC Database Consortium.

Thai Huu Ho, MD, PhD (2011 YIA) – The role of FGF signaling in VEGF-pathway targeted therapy resistance: Data from patients and model systems.     

David S. Hong, MD (2004 YIA) – First-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors.

Jenny J. Kim, MD (2010 YIA) – Overexpression of IGF1R to predict outcome in invasive urothelial carcinoma of urinary bladder.

Ana M. Molina, MD (2010 YIA) – A phase Ib clinical trial of the multitargeted kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma.

Our Grants and Awards Program and the resulting cancer advances would not be possible without the generosity of donors who share our vision to create a world free from the fear of cancer. Please make a donation and join us as we work to support the future of cancer research.